Targets › B3H3
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2034.
Open in Phaseline: the race on B3H3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| St. Jude Children's Research Hospital | SJCARB7H3_41BBL B7-H3-directed CAR T cell therapy with 4-1BB costimulatory domain | B3H3 | Phase 2 | Pediatric Osteosarcoma | Dec 2034 |
Pediatric Osteosarcoma (1)
small molecule (1)
St. Jude Children's Research Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.